Multivariate analysis of prognosis in patients with HDCA/CY/TBI compared with CY/TBI
| Variables . | Overall mortality . | Tumor-related mortality . | NRM . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | |
| Conditioning | ||||||
| CY/TBI | Reference | Reference | Reference | |||
| HDCA/CY/TBI | 0.56 (0.45-0.69) | <.01* | 0.50 (0.38-0.67) | <.01* | 0.94 (0.67-1.33) | .73 |
| Sex | ||||||
| Female | Reference | Reference | Reference | |||
| Male | 1.35 (1.10-1.65) | <.01* | 1.18 (0.90-1.55) | .22 | 1.32 (0.96-1.82) | .08 |
| Age, years | ||||||
| <50 | Reference | Reference | Reference | |||
| ≥50 | 1.46 (1.15-1.84) | <.01* | 1.16 (0.84-1.61) | .37 | 1.50 (1.05-2.15) | .03* |
| PS | ||||||
| 0-1 | Reference | Reference | Reference | |||
| 2-4 | 1.80 (1.33-2.43) | <.01* | 1.57 (1.03-2.38) | .03* | 1.23 (0.72-2.11) | .44 |
| CMV serostatus | ||||||
| Negative | Reference | Reference | Reference | |||
| Positive | 1.22 (0.93-1.61) | .15 | 1.43 (0.97-2.11) | .07 | 1.00 (0.67-1.49) | 1.00 |
| Disease risk | ||||||
| Standard | Reference | Reference | Reference | |||
| High | 2.23 (1.78-2.79) | <.01* | 3.94 (2.81-5.52) | <.01* | 0.83 (0.60-1.14) | .25 |
| Pretransplant therapy period, days | ||||||
| ≤200 | Reference | Reference | Reference | |||
| ≥201 | 1.04 (0.85-1.28) | .71 | 0.98 (0.74-1.29) | .88 | 1.11 (0.80-1.53) | .53 |
| HLA mismatch | ||||||
| Matched | Reference | Reference | Reference | |||
| Mismatched | 0.75 (0.46-1.21) | .23 | 0.84 (0.44-1.62) | .61 | 0.84 (0.39-1.83) | .67 |
| ABO mismatch | ||||||
| Matched | Reference | Reference | Reference | |||
| Minor | 0.67 (0.51-0.87) | <.01* | 0.93 (0.66-1.31) | .67 | 0.58 (0.38-0.90) | .02* |
| Major | 0.70 (0.54-0.92) | .01* | 0.77 (0.53-1.12) | .17 | 0.90 (0.61-1.35) | .62 |
| Both | 0.94 (0.70-1.25) | .65 | 1.02 (0.68-1.52) | .93 | 1.01 (0.65-1.57) | .95 |
| Variables . | Overall mortality . | Tumor-related mortality . | NRM . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | |
| Conditioning | ||||||
| CY/TBI | Reference | Reference | Reference | |||
| HDCA/CY/TBI | 0.56 (0.45-0.69) | <.01* | 0.50 (0.38-0.67) | <.01* | 0.94 (0.67-1.33) | .73 |
| Sex | ||||||
| Female | Reference | Reference | Reference | |||
| Male | 1.35 (1.10-1.65) | <.01* | 1.18 (0.90-1.55) | .22 | 1.32 (0.96-1.82) | .08 |
| Age, years | ||||||
| <50 | Reference | Reference | Reference | |||
| ≥50 | 1.46 (1.15-1.84) | <.01* | 1.16 (0.84-1.61) | .37 | 1.50 (1.05-2.15) | .03* |
| PS | ||||||
| 0-1 | Reference | Reference | Reference | |||
| 2-4 | 1.80 (1.33-2.43) | <.01* | 1.57 (1.03-2.38) | .03* | 1.23 (0.72-2.11) | .44 |
| CMV serostatus | ||||||
| Negative | Reference | Reference | Reference | |||
| Positive | 1.22 (0.93-1.61) | .15 | 1.43 (0.97-2.11) | .07 | 1.00 (0.67-1.49) | 1.00 |
| Disease risk | ||||||
| Standard | Reference | Reference | Reference | |||
| High | 2.23 (1.78-2.79) | <.01* | 3.94 (2.81-5.52) | <.01* | 0.83 (0.60-1.14) | .25 |
| Pretransplant therapy period, days | ||||||
| ≤200 | Reference | Reference | Reference | |||
| ≥201 | 1.04 (0.85-1.28) | .71 | 0.98 (0.74-1.29) | .88 | 1.11 (0.80-1.53) | .53 |
| HLA mismatch | ||||||
| Matched | Reference | Reference | Reference | |||
| Mismatched | 0.75 (0.46-1.21) | .23 | 0.84 (0.44-1.62) | .61 | 0.84 (0.39-1.83) | .67 |
| ABO mismatch | ||||||
| Matched | Reference | Reference | Reference | |||
| Minor | 0.67 (0.51-0.87) | <.01* | 0.93 (0.66-1.31) | .67 | 0.58 (0.38-0.90) | .02* |
| Major | 0.70 (0.54-0.92) | .01* | 0.77 (0.53-1.12) | .17 | 0.90 (0.61-1.35) | .62 |
| Both | 0.94 (0.70-1.25) | .65 | 1.02 (0.68-1.52) | .93 | 1.01 (0.65-1.57) | .95 |
Statistically significant.